Notice: amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `pre_get_posts` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the theme with slug `publisher` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/runcloud/webapps/techilive/wp-includes/functions.php on line 5313
泵给药短效多激素组合专利申请将Adocia临床研究扩展到肥胖症领域 -



里昂, May 26, 2021 (GLOBE NEWSWIRE) — Adocia (巴黎泛欧交易所:FR0011184241 – ADOC),一家处于临床阶段的生物制药公司,专门开发蛋白质和多肽的创新配方,今天宣布,已提交了三项专利申请针对治疗代谢性疾病,包括肥胖症,NASH(非酒精性脂肪性肝炎),2型糖尿病和神经退行性疾病。此三项专利涉及通过泵给药的短效激素组合。胰高血糖素-艾塞那肽(BioChaperone® GluExe)的组合在肥胖小鼠群体中获得的首个临床前结果显示,治疗14天1后,小鼠体重减轻量为25%,而单独使用艾塞那肽减轻量则为15%。目前同样具有良好效能的第二种组合普兰林肽和艾塞那肽(PramExe)正在开发中。所使用的泵均为已经上市的用于胰岛素治疗的泵,尤其是易于使用且适合于此目的的贴片式泵。 使用者可以调整最大耐受剂量,从而优化其获益/风险平衡。

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.


For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – The content will be deleted within 24 hours.

Leave a comment